fb-pixelThe Latest in Financial & Business News - The Boston Globe Skip to main content

More Life Sciences Headlines

Deciphera to be acquired by Japanese drug firm for $2.4 billion

Ono Pharmaceutical will pay $25.60 per Deciphera share in cash, a premium of nearly 75 percent on the Waltham cancer biotech’s closing price of $14.65 on Friday.

Biogen stock climbs on strong Alzheimer’s drug sales

The Cambridge firm on Wednesday reported a first-quarter profit that exceeded estimates as it cut costs and sales of its closely watched Alzheimer’s drug, Leqembi, surpassed expectations.

Sage Therapeutics stock plunges 20 percent after Parkinson’s drug fails study

It was the latest setback for the Cambridge biotech, which in August announced it would lay off 40 percent of its workforce.

Neumora Therapeutics shares fall after rabbits dosed with schizophrenia drug have convulsions

Shares of Neumora Therapeutics fell more than 15 percent Monday morning after an announcement that a clinical trial was paused.

Doctors protest cost of Vertex cystic fibrosis drug as its scientists prepare to receive $3 million ‘Oscars of Science’ award

The controversy threatened to mar a celebrity-studded celebration for researchers who developed new life-saving drugs.

Vertex buying Seattle biotech for $4.9 billion, its biggest acquisition ever

The Boston-based drug company is acquiring Alpine Immune Sciences, a developer of immunotherapies, for $65 a share.

Seaport Therapeutics has $100 million to develop new ways to treat mental disorders

The founders of Karuna Therapeutics, the Boston biotech that was bought by Bristol Myers Squibb for $14 billion, have launched a new company.

Cambridge firm Amylyx pulls ALS drug from market, lays off 70 percent of its staff

The move comes four weeks after the biotech reported that its controversial and costly drug for amyotrophic lateral sclerosis failed to provide any benefit to patients in a large clinical trial.